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C1Q, a subunit of the first component of complement, enhances the
binding of polymeric lgG to human renal mesangial cells (HMC).
Marieke E.A. van den Dobbeisteen, Ngaisah Kiar, Willeke E.M.
Shroejjers, Leendert A. van Es, Fokko J. van der Woude, and Mo-
hamed R. Daha, Department of Nephrology, University Hospital
Leiden, The Netherlands. Hypercellularity and accumulation of extra-
cellular matrix within the glomerulus are hallmarks of glomerular
disease. The mesangium plays an important role in processes of
inflammation in the kidney, Previous studies showed that IgG can bind
to rat mesangial cells (MC) via Fey receptors. Since complement is an
important mediator in processes of inflammation, we investigated
whether C1Q was able to influence the binding of polymeric IgG to
HMC. Human IgG was labeled with 125! and heat aggregated to obtain
polymeric IgG (AIgG). Incubation of MC with '251-AIgG resulted in a
dose- and time-dependent binding to MC. Binding of '251-AIgG to MC
resulted in 87 11 ng '251-AIgG bound per io cells which was
reversible in the presence of excess unlabeled AIgO or Fe fragments
and not in the presence of aggregated F(ab')2 or human serum albumin
(HSA). HMC incubated with '251-C1Q exhibited a dose- and time-
dependent binding of 1251-C1Q to MC. Binding of '251-C1Q to HMC
resulted in 320 25 ng '251-CIQ bound per lO cells which could be
inhibited by increasing concentrations free C1Q and CIQ stalks and not
by HSA. Immunoprecipitation of the putative CIQ receptor from MC
revealed the presence of a single band of 66-68 kD on 10% SDS-PAGE
under reducing conditions. To investigate whether C1Q influenced the
binding of 125j AIgG to HMC, these cells were incubated with constant
amounts of '251-AIgG together with increasing concentrations of CIQ.
The binding of '251-AIgG to HMC was enhanced 2- to 17-fold by C1Q in
a dose-dependent fashion. Heat inactivated C 1Q or CI Q stalks were not
able to enhance the binding of '251-AIgG to HMC. In addition there was
a relation between the size of the AIgG and the enhanced binding by
C1Q. These results provide evidence for the existence of Fey and C1Q
receptors on HMC. The complement component CIQ is able to
increase the binding of polymeric IgG to HMC, and thereby enhance
the potential for inflammation.
Complement depletion abolishes IgA-mediated glomerular inflamma-
tion in rats. R.K. Stad, D.J. van Gjjlswzjk-Janssen, L.A. van Es, and
M.R. Daha, Department of Nephrology, Universal Hospital Leiden,
Leiden, The Netherlands. Recently, we developed an acute model for
IgA-mediated glomerular inflammation in rats. It was shown that
polymeric (p-) but not monomeric (m-) IgA containing immune com-
plexes induce acute nephritis characterized by the activation of com-
plement (C), the presence of intraglomerular macrophages and protein-
uria. In the present study, we investigated the role of C in this
IgA-mediated nephritis. Therefore, rats were pretreated either with
Cobra venom factor (CVF) or PBS followed by introduction of mesan-
gial IgA deposits. Upon deposition of pIgA in the mesangial area, acute
proteinuria was observed only in normocomplementemic rats and not in
C depleted animals. Immunofluorescent analysis revealed deposition of
C3 and C6 in a pattern identical to that of IgA in the glomeruli of normal
rats. Rats pretreated with CVF displayed clear mesangial deposition of
IgA in the absence of C3 and C6. In none of the two groups were C4
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deposits seen, indicating activation of C via the alternative pathway. In
normocomplementemic animals deposition of IgA together with C3 was
associated with an average influx of 4.8 1.7 macrophages per
glomerular section at day 2 as detected by the ED1 monoclonal
antibody. C-depleted rats receiving pIgA also showed an influx of
monocytes reaching values of 6.2 1.2 and 4.2 1.1 monocytes per
glomerular section at day 1 and day 2, respectively. However, no
proteinuria was seen. To obtain insight into the mechanisms of mono-
cyte influx in the CVF treated rats, we also analyzed the number of
monocytes per glomerular section in rats receiving only CVF and no
IgA. There was an increase in the number of monocytes of 7.9 3.3 per
glomerulus at 24 hours following CVF administration. These studies
strongly suggest a role for the terminal components of complement in
IgA mediated glomerular injury. However, further studies are required
to elucidate the true mechanism of glomerular injury in this model,
Molecular cloning of the heparan sulfate proteoglycan (HSPG) from the
human glomerular basement membrane. L.P. W.J. van den Heave!, M.
de Groat, J.H. Veerkamp, L.A.H. Monnens, and J.H.M. Berden.
Departments of Biochemistry, Paediatrics and Nephro!ogy, University
of NUmegen, NUmegen, The Netherlands. To characterize the human
GBM HSPG in more detail, the primary structure of a large HSPG core
protein was determined from eDNA clones. Using the murine eDNA
clones for Engelbreth-Holm-Swarm HSPG, we screened a specific
primed eDNA library from human kidney and isolated 6 different cDNA
clones. The remainder of the sequence was cloned by reverse tran-
scriptase PCR. The complete nucleotide sequence, as well as the
deduced amino acid sequence, showed almost complete homology with
the human perlecan described previously from the fibrosarcoma cell
line and from colon carcinoma cells. The eDNA sequence codes for a
466 kDa protein with a 21-residue signal peptide. Also, the multidomain
structure was observed. Polyclonal antibodies were prepared against
synthetic peptides derived from the N- and C-terminus of the GBM
HSPG molecule (N-terminus: VTHGLRAYDGLSL; C-terminus:
QHRAQAGANTRPCPS). In indirect immunofluorescence studies on
human kidney sections these antibodies displayed a linear fluorescence
of all renal basement membranes. An in vitro expression vector (in
pET8c) was prepared for domain III of the core protein. The E. coli
expressed recombinant protein and reacted in ELISA and Western
blotting studies with polyclonal and monoclonal (2 out of 18) antibodies
prepared against isolated human GBM HSPG. These observations give
the first direct evidence that the entire human perlecan molecule is
present in the human GBM. in vitro expression vectors are in prepa-
ration for the 5 different structural domains of HSPG. The recombinant
proteins obtained with these vectors will be used for studies on the
structural and functional role of these domains in the GBM.
No change in glomerular heparan sulfate despite altered renal hemo-
dynamics and selective proteinuria in experimental diabetes. J. van den
Born, A.A. van Kraats, M.A .H. Bakker, K.J.M. Assmann, L.P. W.J.
van den Heave!, J.H. Veerkamp, and J.H.M. Berden, Departments of
Nephrology, Pathology and Biochemistry, University Hospital Ny-
megen, The Netherlands. Heparan sulfate (HS) is the strongly anionic
side chain of heparan sulfate proteoglycan (HSPG), the major proteo-
glycan within the GBM, and is thought to be responsible for the
charge-selective properties of the glomerular capillary wall (GCW). In
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diabetes alterations in glomerular HS have been described. It has been
suggested that glomerular hyperfiltration is important for the induction
of diabetic nephropathy. Our hypothesis is that altered renal hemody-
namics can give rise to structural changes in the GCW (for instance
HS), leading to proteinuria. To test this, we performed a longitudinal
study during 8 months in 15 male Wistar-MUnich rats that were made
diabetic by an i.v. injection of 55 mg streptozotocinlkg body wt. During
the whole study a low dose of insulin was administrated to achieve
blood glucose levels between 20 to 25 mM/liter. For controls, 5 normal
rats were studied. During the whole period, GFR (51Cr-EDTA) was
increased significantly. Concomitantly, the diabetic rats developed
albuminuria (at 8 months: diabetic rats 42 13 mg/24 hr; control rats 0.5
0.2 mg/24 hr; P < 0.0002). Moreover, the selectivity index (SI)
(clearance IgG/clearance albumin) decreased in the diabetic rats (SI at
6 months: 0.29 0.08, at 8 months: 0.20 0.04, P < 0.0002 in paired
Wilcoxon; control rats SI at 6 months: 0.38 0.17, at 8 months: 0.39
0.17, p:NS; diabetic vs. control rats at 8 months: P <0.05). At 8 months
GFR and ERPF ('25iodohippurate) were measured simultaneously,
kidneys were removed for light microscopy and immunofluorescence
and for the determination of the glomerular HS content after extraction
in inhibition-ELISA by antiHS mAb JM-403. GFR and ERPF were
increased significantly, while FF and MAP were unchanged. On light
microscopy glomerular enlargement and mesangial expansion were
observed. The intensity of glomerular basement membrane staining for
laminin, collagen IV, HSPG-core protein and HS-side chain was
unchanged. The glomerular content of HS was also unchanged (diabetic
rats 11.9 5.5 g HS/mg protein; control rats 7.8 2.0 pg HS/mg
protein). In conclusion, although the GFR and ERPF were increased
and diabetic nephropathy with selective proteinuria developed, the
glomerular HS content did not change significantly. This suggests that
a decrease of the net negative charge of the GCW in this model of
diabetes is not due to a diminished content of glomerular HS.
Recognition of a tissue-specific polymorphism by graft infiltrating T cell
clones isolated from a renal allograft with acute rejection. B.A. Yard,
F.J.H. Claas, M.R. Daha, L.A. van Es, and F.J. van der Woude,
Department of Nephrology, University Hospital Leiden, Leiden, The
Netherlands. The immune response during renal allograft rejection may
be directed against renal specific antigens. We conducted a study to
demonstrate tissue specific recognition of proximal tubular epithelial
cells (PTEC) by graft infiltrating cells (GIC) and cloned GIC. Both
PTEC and GIC were isolated from the same rejected kidney. GIC were
exclusively cytotoxic against donor PTEC (40% specific 51Cr release)
but not against PHA stimulated spleen cells. Pretreatment of PTEC
with IFN gamma did not result in an increased susceptibility to lysis.
Tissue specific recognition could not be explained by a quantitative
difference in cell-surface MHC expression as measured by FACS.
Susceptibility to lysis of PHA blasts could not be achieved by culturing
these cells in PTEC medium or in the presence of PTEC. From the GIC
line 18 CTL clones were isolated. Four clones were also cytotoxic
against donor PHA blasts, demonstrating not only the polyspecificity of
the T cell line but also that tissue-specificity was not due to an intrinsic
non-susceptibility of the PHA blasts. Nine tissue-specific clones were
selected for further analysis. They were all CD8 and TCR aJ3.
Cytotoxicity was inhibited by anti-CD3, anti-CD8, anti-MHC class I
and anti-CD18 MoAb, ranging from 100% to 50%. Only PTEC express-
ing HLA-A31 were recognized by all clones. However, there were three
clones that did not lyse all HLA-A3l PTEC lines, suggesting recog-
nition of an HLA-3 1, tissue associated polymorphism. These results
show for the first time that polymorphic human renal specific antigens
can be recognized by GIC in vitro and thus may play an important role
in the rejection of a renal allograft.
Ovariectomy decreases plasma triglycerides and completely prevents
proteinuria and glomerulosclerosis in uninephrectomized female analbu-
minemic rats. J.A. Joles, H. van Goor, J. Grond, H.A. Koomans, R.J.
Hené, and A. van To!, Department of Nephrology, Utrecht; Depart-
ment of Pathology, Groningen; and Department of Biochemistry,
Rotterdam, The Netherlands. Female analbuminemic rats (NAR) are
severely hyperlipidemic as compared to male NAR. After uninefrec-
tomy (UNX), only female NAR develop proteinuria and glomerular
sclerosis (GS). To determine whether estrogen was responsible for the
development of renal injury in uninephrectomized female NAR, female
NAR were subjected to UNX, UNX + bilateral ovariectomy (OVX), or
sham operation (CON). The UNX and UNX + OVX female NAR
developed comparable degrees of hyperfiltration: the 1 hour EDTA
clearance increased to values between 130 and 150% of the mean CON
one-kidney filtration at 1, 4 and 8 weeks after UNX, and the 24 hour
creatinine clearance increased to between 120 and 185% at 6, 11, and 20
weeks after UNX. However, the UNX + OVX female NAR had
markedly decreased triglyceride levels and developed no proteinuria or
OS.
weeks after UNX
11 20 30 40
proteinuria mg/day
CON(N=8) 4±0.4 7±0.9 8±1.2 14±7
UNX(N=8) 5±0.9 3l±l2a 10738b 13031b
UNX ÷ OVX 3 0.2 4 0.7 3 0.2 3 0.3(N = 6)
plasma triglycerides
mmol/liter
CON 2.8 0.3 3.3 0.6 5.7 0.8
UNX 2.6 0.3 4.3 0.4 5.8 1.3
UNX + OVX 1.3 01b 1.8 03b 7 04b
Plasma (p) apolipoprotein (apo) A-I, B and E (mg/dl; immunoelectro-
phoresis), glomerular apo A-I, apo B, and apo E deposits (immunohis-
tochemistry), GS and glomerular lipid deposition (GLD) were measured
after 43 weeks.
p apo A-I p apo B p apo E GS GLD score
CON 151±6 185±7 32±2 0 5±2.3
UNX 214 22 284 24 40 2 48 1? 76 18
UNX + OVX 117 6 180 5 48 2 0 2 0.4
ap< 0.05
Strong apo A-I and trace apo B and apo E deposits in glomerular
epithelium and weak mesangial apo B and apo E were observed in
UNX. Trace epithelial apo A-I and E, but no glomerular apo B
deposition was observed in CON and UNX + OVX. GS as well as
mesangial lipid and apo E deposits were absent in UNX ÷ OVX in the
presence of high plasma apo E levels. The low triglyceride and
increased apo E levels observed after ovariectomy in uninephrecto-
mized female NAR may play a role in the protective effect of ovariec-
tomy on glomerular permselectivity and morphology in this model.
Muscarinic receptor subpopulations in the forearm vascular bed of
normotensive humans. T.A. Bruning, P.C. Chang, M.G.C. Hendriks,
E.A.P. Kuypers, and P.A. van Zwieten, Department of Pharmacother-
apy, Academic Medical Centre, Amsterdam, and Departments of
Nephrology and Hospital Pharmacy, University Hospital Leiden, Lei-
den, The Netherlands. So far, little evidence has been presented for the
existence of muscarinic (M)-receptor subtypes in human peripheral
blood vessels. Animal experiments indicate the involvement of the
M3-receptor in endothelium-dependent relaxation of vascular smooth
muscle, whereas the "nitric oxide (NO)-pathway" is presumed to play
a role in that process. To further assess the vasodilation induced by
acetylcholine (ACh) and methacholine (MCh), and to analyze the role of
M-receptor subtypes in the forearm of normotensive volunteers (N =
12), we infused ACh (dose range 1—1000 ng/kg/min) in the presence of
saline, and MCh (dose range 0.1—1000 ng/kglmin) in the presence of
saline, the non-selective muscarinic antagonist atropine (dose range
0.6—60 ng/kg/min), the M1-receptor selective antagonist pirenzepine
(dose range 0.8—800 ng/kglmin), the M2-receptor selective antagonist
AF-DX 116 (dose range 8—8000 nglkglmin), and the guanylate-cyclase
inhibitor and NO-scavenger methylene blue (1000 ng/kglmin), using
automated R-wave triggered venous occlusion plethysmography. By
calculating the plasma concentrations of the infused compounds we
were able to obtain EC50-values and perform "Schild analysis." ACh
and MCh both caused dose-dependent vasodilation (EC50-values of 1.34
vs. CON: a p < 0.05; b P <0.01; mean SEM
1194 Abstracts
pM and 64.8 nM, respectively). The dose-response curve (DRC) of MCh
was shifted to the right by atropine, pirenzepine, as well as by AF-DX
116 (apparent pA2-values of 7.92, 6.70, and 5.99, respectively; slopes
not different from unity). Methylene blue did not affect the DRC of
MCh. The apparent 20-fold higher potency of MCh compared to ACh
may be explained by the rapid degradation of ACh in the plasma. The
pA2-values of pirenzepine and AF-DX 116 are comparable to values
reported for in vitro experiments. The present technique enables us to
perform muscarinic receptor characterization using different competi-
tive antagonists in the vascular bed of the human forearm. The results
so far obtained confirm the functional relevance of muscarinic receptors
in peripheral human blood vessels. The M3-receptor appears to be of
predominant interest.
Inhibition of endothelium derived relaxing factor (EDRF) synthesis
aggravates renal vasoconstriction in endotoxemic rats. A.A. van Lambal-
gen, M.F. Mulder, E. Huisman, A. Heemskerk, G.C. van den Bos, L.G.
ThUs, and A.J.M. Donker, Laboratorium for Physiology, ICaR-VU,
Research School Free University, Amsterdam, The Netherlands.
EDRF (mainly nitric oxide: NO) seems to be involved in the normal
regulation of renal blood flow (RBF). We hypothesized that during
endotoxin shock, when RBF reduces, EDRF is also important to
mitigate the vasoconstricting actions of endotoxin or of the mediators
induced by it. Therefore, we studied the effects of inhibition of the NO
production by N°-nitro-L-arginine (L-NNA, a L-arginine analogue) on
endotoxin induced changes in RBF and renal vascular resistance
(RVR), Two groups of 6 anesthetized male rats (circa 300 g) received an
infusion of E. coli 0127:B8 endotoxin (8 mg/kg) from t = 0 to t = 60
minutes. To prevent a marked decrease in cardiac output (CO) during
shock, rats also received 12 mI/kg . hr Haemaccel® from t = —5 to t =
60minutes. One group (LNNA) received at t = —30mm 0.1 mg L-NNA
per rat, the other group (EC) remained untreated. RBF and CO were
measured with radioactive microspheres at t = 0 and 60 minutes. We
also measured mean arterial pressure (MAP), systemic vascular resis-
tance (SVR) and RVR. Although injection of L-NNA caused a slight
increase in MAP and SVR, no significant differences for any of the
measured variables were found between the groups at t = 0 (that is,
before starting endotoxin infusion). After endotoxin infusion MAP did
not change significantly in both groups, CO decreased more in the
LNNA than the EC group (by —35% vs. —23%, P < 0.05), and SVR
increased only in the LNNA group (by +39% vs. +3%, P < 0.05). RBF
decreased more and RVR increased more in the LNNA than in the EC
group (by —74% vs. —53% and +203% vs. +68%, respectively; P <
.05). Our results show that a dose of L-NNA, which does not affect
basal renal hemodynamics, has severe implications for RBF during
endotoxemia. EDRF/NO production thus seems essential for the kid-
ney in endotoxemic rats because it will prevent severe renal vasocon-
striction.
Renal perfusion of protelnase 3: A novel elastinolytic enzyme and target
antigen of anti-neutrophil cytoplasmic antibodies. E. Brouwer, K.M.
Dolman, M.G. Huitema, P.A. Kiok, R. Goldschmeding, J.J, Weening,
and C.G.M. Kallenberg, Departments of Clinical Immunology and
Pathology, University Hospital Groningen, Groningen; Department of
Pathology, Academic Medical Center, Amsterdam; and Department of
Immunological Haematology, Central Laborato,y of the Netherlands
Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's Granu-
lomatosis (WG) are directed to proteinase 3 (PR3). PR3 is a recently
described elastinolytic enzyme with a molecular weight of 29 kD and an
isoelectric point of 9.1. After stimulation of neutrophils PR3 is released
from the azurophilic granules. In vitro PR3 cleaves fibronectin, laminin,
vitronectin, and collagen type IV [all components of the glomerular
basement membrane (GBM)], and after intratracheal insufflation in
hamsters PR3 causes emphysema. Since renal lesions in WG are
characterized by GBM disruption and necrosis, we hypothesized that
PR3 may contribute to renal damage in WG. To test this hypothesis we
perfused the left kidneys of rats in a closed blood-free system with 50 pg
enzymatically active PR3. We measured urinary protein excretion. Rats
(N = 10) were sacrificed at 10 minutes, 4 hours, 24 hours, 4 days, and
10 days after perfusion. Renal tissue was processed for lightmicros-
copy, immunofluorescence, and immunoelectronmicroscopy, As con-
trols rats were perfused with phosphate buffered saline. Low-grade
proteinuria was found within the first 24 hours, at 4, and at 10 days after
perfusion. At 10 minutes after perfusion PR3, as detected by immuno-
fluorescence, was localized in a granular pattern along the GI3M and
was also present inside tubular epithelial cells. At later time points
glomeruli were negative for PR3. No gross morphologic abnormalities
were found. In conclusion, in vivo renal perfusion of PR3 caused only
low grade proteinuria and no necrosis nor morphologic changes within
the perfused kidneys.
Mechanism of the acute effects of ACE-inhibition on renal hippuran
extraction in normal rats. G.J. Navis, D. de Zeeuw, and P.E. de Jong,
State University Hospital, Groningen, The Netherlands. ACE-inhibi-
tors (ACEi) can lower the renal extraction (Ex) of hippuran (Hip), thus
affecting Hip's reliability as a renal blood flow tracer. The mechanism of
this fall in ExHip is unknown, but it has been suggested to be due to a
reduced tubular secretion of Hip. The fall in ExHip is most pronounced
in situations where filtration also decreases after ACEi (such as renal
artery stenosis). As Hip is not only secreted, but also filtered, this could
imply that the fall in ExHip after ACEi is due to decreased glomerular
filtration. We therefore investigated the effects of ACEi on renal Hip
handling. Male Wistar rats were anesthetized, instrumented, and con-
tinuously infused with tracer doses of '311-Hip and 1251-iothalamate
(lot). After steady-state was reached, renal clearance and Ex-ratio's of
both tracers were measured before and after low doses of different
ACE-inhibitors (15 pg lisinopril, N = 5; 75 pg captopril, N = 5; 15 pg
enalaprilat, N = 4), or vehicle (N = 7). Blood pressure fell after ACEi,
but not after vehicle. Renal plasma flow and GFR did not change
significantly after either ACEi or vehicle. Data on renal extraction
(mean SEM) are shown in the table. Glomerular extraction of Hip(EgIH) was derived from the Ex of lot. Tubular extraction ratio of Hip
(Etubll) was calculated by subtracting the filtered fraction of Hip
(EgIH) from the arterial Hip level.
Baseline
Extraction ratio %
N ExHip EgIH EtubH
vehicle 7 0.78 0.01 0.27 0.02 0.71 0.01
ACEi 14 0.80 0.02 0.29 0.02 0.73 0.02
a P < 0.05, vs. baseline
Treatment
Change from baseline %
N ExHip EgIH EtubH
vehicle 7 0 2 11 16 —1 4
ACEi 14 —9 2 —21 7 —9 3a
Thus, ExHip, EgIH and EtubH decrease after ACEi in normal rats,
even in the absence of detectable changes in GFR and RPF with these
low doses. Changes in both glomerular and tubular Hip handling
contribute to the decrease in ExHip after ACE1.
Ankle edema with nifedipine is not primarily due to sodium retention.
H.W. van Hamersvelt, M.E.E. van Kasteren, H.J. Kloke, R.A.P.
Koene, and F, Th.M. Huysmans, Department of Nephrology, Univer-
sity of NUmegen, Nzjmegen, The Netherlands. Ankle edema is a
common side effect of antihypertensive treatment with calcium entry
blockers (CEB), such as nifedipine (Nif). Edema formation with other
vasodilating drugs has been ascribed to renal sodium retention second-
ary to blood pressure reduction. However, CEB also have an acute and
probably chronic natriuretic effect, which makes such a mechanism less
likely. Therefore, we measured foot volume and natriuresis in sitting
position in 12 healthy volunteers (6 females and 6 males) for 15 minutes
before and 120 minutes after oral placebo (Plac) or 20 mg of Nif
(capsules), given in a randomized, crossover way. Additionally, 40 mg
of furosemide (Fur) or saline (Sal) were given i.v. 40 minutes after Nif.
Foot volume was measured continuously with a new method (I.M.
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ValkR) using a sensitive balance to measure water displacement (intra-
individual CV; 0.27%). Body weight (BW), hematocrit (Ht), serum
protein (Prot), and serum albumin (AIb) were also measured. Nif
increased foot volume more than Plac (+22 3 and + 11 3 g,
respectively, mean SEM, P = 0.003). Simultaneously, Nif increased
fractional sodium excretion (FENa, mean absolute +0.5 0.2 vs.
—0.2 0.1% with Plac, P = 0.003), Ht (+ I 3 vs. 0 0%, P = 0.002),
and Prot (+ 2.1 0.5 vs. —0.3 0.6 g/l, P = 0.002). Nif had no
significant influence on BW (—0.2 0.1 vs. —0.2 0.1 kg with Plac,
P = NS), urinary flow rate (UFR, +2.9 1.4 vs. +3,7 0.9 mI/mm, P
NS) and AIb (+ 1.6 0.4 vs. +0.1 0.5 g/liter, P 0.07). Addition
of Fur to Nif resulted in massive increases of UFR (+ 10.7 0.8 mI/mm)
and FENa (+6.7 0.3%), a decrease of BW (—0.7 0.0 kg) and
increases of Ht (+2 0%), Prot (+7.2 0.6 g/liter) and AIb (+4.9 0.3
g/liter), all changes P < 0.01 compared to Nif + Sal. However, Fur had
no influence on the Nif-mediated increase in foot volume (+ 19 3 g, P
= 0.17 compared to Nil + Sal). In conclusion, as Nif increases foot
volume and natriuresis simultaneously, edema with CEB cannot be due
to renal sodium retention. Since massive natriuresis with Fur did not
blunt the increase in foot volume with Nif, diuretics are probably less
effective for treatment of the edema caused by CEB.
The antiproteinuric effect of ACEi is more than only renal hemody.
namically mediated. R. T. Gansevoort, D. de Zeeuw, and P.E. de Jong,
University Hospital, Groningen, The Netherlands. The antiproteinuric
effect of ACEi is hypothesized to be directly mediated by changes in
renal hemodynamics. However, clinical studies suggest that the effect
on renal hemodynamics is fully established immediately after start of
treatment, whereas other studies show the antiproteinuric effect to
reach maximum only after several weeks. To clarify this issue we
studied the course of ACEi induced changes in urinary protein excre-
tion, systemic blood pressure and renal hemodynamics in 9 patients
with nephrotic range proteinuria due to non-diabetic renal disease.
Patients adhered to a 50 mmol sodium restricted diet and had no
concomitant therapy. Effects of ACEi were first tested during 8 hours
after administration of enalaprilat (10 mg i.v.). A similar study day on
placebo medication served as time control. The antiproteinuric effect
after acute ACEi showed a significant correlation with the induced
changes in ERPF, RVR and FF (r = 0.73, P < 0.05; r = 0.73, P < 0.05;
r = 0.90, P < 0.01, respectively), but not with changes in GFR (r =
0.38, NS). ACEi was continued with 10 mg enalapril t.i.d. and patients





day —7 day 1 day 7
MAP mm Hg 94.5 4.2 —11.0 2.l%a —10.6 2.l%a
FF 0.231 0.018 —29,6 l.5%a —17.0 2.6%a
Uprot g/day 6.7 1.3 —15.1 3,7%a —32.7 6.2%a
Mean SE; a P < 0.05 vs. baseline, bp < 0.05 vs. day 7; ANOVA
ACEi 10 mg Recovery
day 56day 14 day 28
MAP mm Hg —12.8 2.3%a —12.9 2.5%a —2.4 1.4%
FF —16.8 2.8%a —15.9 4.0%a —3.4 2.0%
Uprot g/day —46.3 2.5%a —54.0 2.5%' —10.0 6.7%a
Whereas the effect on blood pressure and renal hemodynamics was
already maximal on day 1 of ACEi, the antiproteinuric effect only
gradually reached its maximum on day 28. These data suggest that the
acute antiproteinuric response to ACEi is related to renal hemodynamic
changes. During continued ACEi however, also other, non-hemody-
namic mechanisms appear to become important, resulting in a maximal
antiproteinuric effect only several weeks after initiation of therapy.
The fibrinolytic system in the hemolytic uremic syndrome: in vivo and
in vitro studies. N.C.A.J. van de Kar, V. W.M. van Hinsbergh, E.J.P.
Brommer, and L.A.H. Monnens, Gaubius Laboratory, TNO-IVVO,
Leiden, and Department of Pediatrics, Sint Radboud Hospital, Nz)me-
gen, The Netherlands. Fibrinolytic parameters and von Willebrand
factor (vWF) antigen were measured in the plasmas of 10 patients with
the hemolytic uremic syndrome (HUS). Samples were taken at presen-
tation and again two weeks later, before and after infusion of 1-des-
amino-8-arginine vasopressin (DDAVP). Compared with the plasmas of
healthy control children, mean levels of tissue-plasminogen activator
(t-PA) antigen, plasminogen activator inhibitor I (PAl) activity, as well
as vWF were significantly elevated in HUS patients on admission. No
response of these parameters was seen when DDAVP-infusion was
given on admission. After two weeks, t-PA antigen and vWF had
partially returned to basal values, and t-PA antigen rapidly increased
again after DDAVP-infusion. This suggests a decrease in the activation
of the endothelium and a general amelioration of the DDAVP response.
In order to investigate whether verocytotoxin (VT) contributes to the
alteration of the fibrinolytic system found in HUS patients, purified
verocytotoxin-I (VT-I) was added to the media of cultured human
umbilical endothelial cells. Addition of VT-i alone did not change the
production of t-PA, PAl-i and vWF antigen by these cells. However,
when the endothelial cells were pre-incubated with tumor necrosis
factor a (TNFa) to increase the number of VT-I receptors, VT-I
induced a marked decrease of the synthesis of t-PA, PAl-I and vWF.
This was due to a decrease in overall protein synthesis in the TNFa-
VT-i-treated cells. We conclude from this study that the systemic
fibrinolytic parameters measured in plasma of HUS patients are prob-
ably not a direct effect of VT-i on the endothelium, but are sequelae of
the disease in which the intestine and the kidney are predominantly
affected.
Measurement of GFR by "single-shot" injection of inulin. K. W.
FlorUn, W. Prodjosudjadi, J.N.M. Barendregt, J.L.C.M. van Saase,
L.A. van Es, and P.C. Chang, Department of Nephrology and Clinical
Epidemiology, University Hospital Leiden, Leiden, The Netherlands.
For long-term studies there is a need for an accurate and intra-
individually reproducible method for determining GFR. In 14 patients
with autosomal dominant polycystic kidney disease (creatinine clear-
ances 24—120 mI/mm/I .73 m2) the clearance of inulin using the constant
infusion method was compared with the "single-shot" technique.
Triplicate measurements of each method were obtained in 12 out of 14
patients. Plasma inulin was measured using the anthrone method with
correction for glucose in each sample. A high correlation was found
between the total body clearance and the urinary clearance for both the
constant infusion method (r = 0.98) and the single injection technique (r
= 0.95). The coefficient of variation for the total body clearance of
inulin was significantly lower for the constant infusion method and the
single injection technique (5.6% and 6.3%) than for the respective
urinary clearances of inulin (9.9% vs. 9.4%, P < 0.001). A constant
overestimate of the urinary clearance by the total body clearance was
observed with both methods (constant infusion method 11.9 mllmin/
1.73 m2 and single-shot technique 16.3 mI/min/l .73 m2). Using the
individual overestimates, the total body clearance of inulin obtained by
the single injection technique could well replace the conventional
urinary clearance (constant infusion method) with excellent agreement
between both methods. No concentration-dependent clearance of inulin
was observed. The anthrone method for measuring plasma inulin is
sensitive to plasma glucose (regression equation: apparent inulin = 5.9
x glucose in mmol/liter + 20.8; r = 0.96). We conclude that, taking into
account each individual's constant overestimate of urinary clearance by
the total body clearance of inulin, the single-shot total body clearance
possesses the best reproducibility and shows a good agreement with the
conventional urinary inulin clearance.
Amelioration of kidney function with thyroid hormone substitution
therapy in patients with hypothyroidism. R. van Leusen, H.J.M. RUn-
ders, F.H. Bosch, R.A. de Vries, and L. Verschoor, Departments of
Internal Medicine and Nuclear Medicine, Rzjnstate Hospital, Arnhem,
The Netherlands. In a group of 22 patients with primary hypothyroid-
ism defined as a TSH-Ievel  12 mU/liter (Irma-TSH, normal 0.2—3.0
mU/liter), the effect of a slowly increasing dose of thyroxine on the
measured endogenous creatinine clearance (m-ECC), the predicted
ECC using the formula of Cockcroft and Gault (p-ECC), and the
glomerular filtration rate (GFR) were measured. The GFR was mea-
sured by Cr-EDTA single-shot technique using a two compartment
1196 Abstracts
model. Euthyroidism, defined by an obligatory normal TSH-level, was
reached within 3 to 12 months. The serum creatinine level declined from
95.5 18.5 (SD) to 76.4 17.2 smo1I1iter (F < 0.0001), the m-ECC
increased from 94,6 23.2 to 127.2 23.1 mI/mm (P < 0.0001), the
p-ECCfrom 78,1 18.6 to97.l 28.1 rnh/min(P< 0.001), and the GFR
from 88.9 32.8 to 107.4 25.5 mI/mm (P < 0.002) using the two-tailed
paired 1-test. Before commencing therapy the correlations between the
m-ECC, p-ECC and GFR were evaluated. It was shown that these
correlations were positive at a highly significant level (m-ECC vs. GFR
P <0.0001, m-ECC vs. p-ECC P <0.01, p-ECC vs. GFRP <0.0001).
The outcome of the correlation figures is not different from the
euthyroidal state as defined from the literature. In conclusion, an
important gain in GFR can be expected once euthyroidism is reached.
For practical purposes the ECC can be used in the same way as in the
euthyroidal state to estimate the GFR.
Factors associated with reversal of the diurnal rhythm in sodium
excretion in nephrotic syndrome. M.G. Koopman, G.C.M. Koomen,
B.A.C. van Acker, and L. Arisz, Academic Medical Center, Amster-
dam, The Netherlands. Patients with nephrotic syndrome (NS) will
vary in serum albumin concentration, quantity of edema and impair-
ment of renal function. To analyze the impact of these and other factors
on urinary sodium excretion (UN,) and its diurnal variation, we studied
70 patients with NS during 1 to 3 (mean 2.3) days and a regimen of
bedrest and constant Na intake around the clock after an equilibration
period of one week. None of the patients used diuretics. Urine and
blood were sampled every 3 hours. UNa ranged from zero to 170 (mean
47) mmol/24 hr and matched well with dietary intake (r = 0.77; P <
0.001). Equilibrium with UNa higher than 10 mmol/24 hr was reached in
59 patients. In 24 patients (group A) UNa followed a normal diurnal
rhythm with a peak in daytime, in 35 (group B) this was not so (29 x
peak during night, 6 x rhythm absent). Group B differed from A in two
respects: first, group B was more nephrotic than A (serum albumin: 19.5
vs. 24.1 g/liter, P < 0.05; edema: 7.0 vs. 3.8 kg, P < 0.01), and
secondly, group B had signs of more advanced renal disease than A
(GFR: 48.6 vs. 99.0 mI/mm, P < 0.001; number of biopsies with
interstitial fibrosis and tubular atrophy: 20 of 28 vs. 4 of 23, P < 0.00 1).
UNa (49 vs. 63 mmol/24 hr, P > 0.05) and PRA (4.85 vs. 2.76 nglml/hr,
P > 0.05) were similar. Reversal of the UNa diurnal rhythm was
associated with reversal of the rhythms in GFR, ERPF and urine flow
and blunting or reversal of day-night differences in blood pressure and
PRA. Eleven patients had UNa < I mmol/24 hr. With respect to severity
of nephrosis they matched with group B, but in GFR and absence of
tubulointerstitial damage they matched with group A. They were
different from A and B by having a much higher PRA (mean 23.4
ng/ml/hr; P < 0.02 and P < 0.001). In conclusion, with relatively good
GFR and not too severe NS, a normal UNa rhythm is maintained. With
good GFR, but severe NS, Na' is completely retained. Severe NS,
impaired GFR and tubulointerstitial damage leads to a higher UNa4' and
GFR during the night than during the day (reversed rhythms) due to
reentry of edema in the circulation during sleep in the supine position.
Renal and systemic hemodynamic effects of ibopamine in patients with
mild congestive heart failure. A.G. Lieverse, Di. Van Veidhuisen, A.J.
Smit, J.G. ZUistra, S. Mejer, W.D. Reitsma, K.I. Lie, and A.R.J.
Girbes, Department of Internal Medicine, Department of Cardiology,
and Division of Intensive Care, Department of Surgery, University
Hospital Groningen, The Netherlands. The effects of a single dose
ibopamine on systemic and renal hemodynamics, sodium excretion,
PRA and plasma aldosterone concentration (PAC) were investigated in
10 patients (5 1—79 years) with mild congestive heart failure (CHF), class
Il—Ill NYHA. All patients used digoxin and frusemide. After a control
study-day with measurements of renal characteristics, blood pressure
and heart rate, a study-day with simultaneous measurement of systemic
and renal hemodynamics was performed, before and after the adminis-
tration of 100 mg ibopamine. Glomerular filtration rate (GFR) and
effective renal plasma flow (ERPF) were measured simultaneously
using radiopharmaceuticals. A significant increase of GFR, from 77 8
to 85 8 ml/min/l.73 m2, ERPF, from 288 32 to 316 32 ml/minll.73
m2, and cardiac output (CO), from 4.00 0.38 to a maximum of 4.98
0.64 liter/mm, was observed after the administration of ibopamine. The
ratio GFRIERPF representing the filtration fraction (FE) remained
unchanged. The ratio renal blood flow: cardiac output (ERPF/CO)
remained unchanged after the administration of ibopamine. No increase
of sodium excretion was found. No changes in blood pressure, heart
rate, PRA and aldosterone were observed. We conclude that ibopamine
increases both ERPF and GFR in patients with mild CHF, as a
consequence of predominantly systemic hemodynamic effects, with
equal preglomerular and postglomerular renal vasodilation. Ibopammne
caused no significant natriuresis in these salt depleted patients. Neither
were changes in PRA and aldosterone found,
Changes of the functional state of the kidney In the dialysis-free
interval. R.W. van Olden, B.A.C. van Acker, G.C.M. Koomen, R.T.
Krediet, and L. Arisz, Academic Medical Center and Diatel, Amster-
dam, The Netherlands. Urinary volume of hemodialysis patients with
residual renal function increases during the dialysis-free interval (DI).
Nephrons in end-stage kidney disease are supposed to be hypertrophic
with a high fractional sodium excretion. Eleven chronic hemodialysis
patients with residual renal function were investigated during two
identical Dl's of 3 days (DI-!, DI-2) with an interval of one week to
determine changes in glomerular filtration, and excretion of water,
sodium and urea. Two hours before the end of dialysis treatment, inulin
10 g was administered intravenously. Plasma samples were taken at the
beginning and end of DI. Urine samples were taken from daily collec-
tions during the complete DI. Daily calculations were made of: inulin
clearance (CI), urea clearance (CU), fractional sodium excretion
(FENa), electrolyte-free water clearance (CH2O), distal delivery (DD)
and volume reabsorption (VR). Daily urinary volume (V) and sodium
excretion between the two Dl's were equal. Mean urine osmolality was
284 47 mOsml/kg, mean plasma osmolality was 299 6. CI increased
duringDl-l andDI-2from 1.8 1.1 ml/minto2.7 1.2(P'z0.005),CU
from 1.5 1.5 mI/mm to 2.0 0.9 (P < 0.05), FENa from 9.0 5.7%
to 14.5 9.0 (P < 0.05), CH2O from 0.13 0.12 mI/mm to 0.22 0.16
(P < 0.05), DD from 12.6 6.1% to 17.1 6.3 (P <0.05) and VR from
1.4 1.1 mI/mm to 2.1 1.0 (P < 0.02). Mean daily reabsorption of
filtrate is 77 10%. It can be concluded that glomerular filtration and
parameters of water and sodium excretion change during DI. The
increase in VR showed that tubular reabsorption varies with changes in
glomerular filtration in kidneys with residual function.
Cyclosporine does not inhibit the tubular secretion of creatinine. L.B.
Hilbrands, A.J. Hoitsma, J.F.M. Wetzels, and R.A.P. Koene, Univer-
sity Hospital Nmegen, Njjmegen, The Netherlands. A rise in serum
creatinine or a fall in creatinine clearance can be caused by: (a) a
decrease of glomerular filtration rate (GFR), (b) inhibition of the tubular
secretion of creatinine, or (c) a combination of both (a) and (b).
Cyclosporine (CsA) has convincingly been shown to decrease GFR,
and a rise in serum creatinine during CsA therapy is usually attributed
to a decline of GFR. Since CsA has also been demonstrated to have
tubulotoxic properties, it might inhibit the tubular secretion of creati-
nine as well. In that case, finding a rise in serum creatinine could lead
to overestimation of the impairment of renal function. To investigate
the influence of CsA on tubular secretion of creatinine, we simulta-
neously measured the clearance of creatinine and inulin (the latter as a
marker of GFR) during and 4 weeks after cessation of CsA therapy in 18
renal transplant patients. As expected, there was an increase of GFR
(64.2 19.2 vs. 77.9 27.2 ml/min/l,73 m2; P < 0.001) and of
creatinine clearance (87.7 33.6 vs. 99.4 34.4 mllmin/l.73 m2; P =
0.02). Notably, the ratio between the creatinine clearance and GFR (a
measure of the relative contribution of tubular secretion to the clear-
ance of creatinine) did not change significantly (1.37 0.27 vs. 1.33
0.43). In addition, the absolute rate of tubular creatinine secretion did
not increase (172.0 143.2 vs. 132.0 149.8 rmolihr; P = NS). These
observations strongly suggest that CsA does not substantially inhibit
the tubular secretion of creatinine. A rise in serum creatinine after
administration of CsA can thus be attributed completely to a fall in
GFR.
The role of glucocorticold in excretion of an acute potassium load in
patients with mineralocorticoid deficiency (m. Addison) and panhypopi-
tuitarism. M. van Buren, A.J. Rabelink, H.P.F. Koppeschaar, and
H.A. Koomans, Departments of Nephrology and Hypertension and
Endocrinology, University Hospital Utrecht, Utrecht, The Nether-
lands. Glucocorticoid (GC) has been shown to stimulate potassium (K)
excretion in various conditions, but it is still incompletely resolved
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whether its presence is essential for the normal K homeostasis. We
addressed this question in patients with selective GC deficiency (pan-
hypopituitarism) and with combined GC and mineralocorticoid defi-
ciency (m. Addison), studied 24 hours after withdrawal of their regular
substitution therapy. Compared to data in healthy subjects, both basal
K excretion and the kaliuresis after a KCI load (1 mmol/kg body weight
orally) were impaired in either patient group (P < 0.05). Physiological
cortisol suppletion (20 mg 3 hr prior to test, and 1 mg/hr during test)
increased basal K excretion (from 10.6 1.8 to 19.2 1.9 mmol/5 hr,
P < 0.01) and KCI-stimulated kaliuresis (from 47.9 6.1 to 54.8 4.7
mmol/5 hr, P = 0.06) to normal levels in panhypopituitarism. Cortisol
also improved basal K excretion (from 10.2 1.5 to 16.9 3.5 mmol/5
hr, P < 0.05) and KCI-stimulated K excretion (from 31.6 2.5 to 45.2
3.8 mmol/5 hrs, P < 0.05) in m. Addison, although KCI-stimulated K
excretion remained below normal (P < 0.01). The effects of cortisol on
sodium excretion differed between the two patient groups (P < 0.05), in
that only in m. Addison the improved K excretion was associated with
sodium retention. Additional experiments with the purely GC com-
pound dexamethasone (0.5 mg 3 hrs prior to test, and 0.03 mg/hr during
test) in the patients with m. Addison also improved K excretion (P <
0.05), but without the concomitant sodium retention observed after
cortisol. These data speak for a physiological role of GC in potassium
homeostasis, and also suggest that cortisol, as the important endoge-
nous GC hormone, has mineralocorticoid-like effects specifically in the
absence of aldosterone.
Similar effects of captopril and atenolol on renal function in patients
with diabetic nephropathy. L.D. Elving, J.F.M. Wetzels, H.J.J. van
Lier, E. de Nobel, and J.H.M. Berden, Departments of General
Internal Medicine, Nephrology and Medical Statistics, University
Hospital N,jmegen, The Netherlands. In a 2 year prospective, random-
ized study we have compared the effects of captopril (C) and atenolol
(A) on renal function and albuminuria in patients with an early stage of
overt diabetic nephropathy. Fifteen patients (age 37 years) were treated
with C and fourteen (age 39 years) were treated with A. Duration of
diabetes was 26 years in both groups. All patients had signs of diabetic
retinopathy. Six patients on C and two patients on A also received
chiortalidone. At baseline and every 6 weeks mean arterial pressure
(MAP, Dinamap) and 24 hour urinary albumin (UAIbV) and total protein
(U0V) excretion were determined. Every 6 months GFR (plasma
clearance of 51Cr-EDTA) was measured. MAP, UALbV, UprotV and
GFR at baseline and after 2 year treatment (mean of all measurements
during the last 6 months) with both treatments are given in the table.
Captopril Atenolol
baseline 2 year baseline 2 year
MAP mm Hg 110 3 100 2 105 2 101 2b
UMbV mg/24 hr 1915 376 1260 367C 1339 373 951 252°
U0V g/24 hr 3.0 0.5 1.6 Q•4 2.2 0.6 1.3 0.4°
GFR mI/mm 95 6 84 6 97 9 89 9
Values given as mean SE. Baseline values are not significantly
different.
a p < 0.01, ID p < 0.05, P = 0.06 vs. baseline.
The rate of decline of GFR was identical with both treatments: —4.9
2.1 and —3.7 1.6 ml/min/year for C and A respectively. The greatest
effect of both treatments on MAP, albuminuria and GFR was observed
during the first six months. When calculated from six months onwards
the decline in GFR was also not significantly different between the two
treatments: —3.8 2.3 for C vs. —1,8 2.2 mI/mm/year for A. An
increase in proteinuria was seen in four patients on C and in one patient
on A. When these patients were excluded from the analysis, there was
still no significant difference in decline of GFR between the two
treatment groups. In conclusion, captopril and atenolol are equally
effective in protection of renal function in patients with diabetic
nephropathy.
On the renal pathophysiology of a family with hypomagnesemia,
hypokalemia (Bartter/Gitelman syndrome) and chondrocalcinosis. T.J.
Smilde, A.R.M.M. Hermus, J.F. Haverman, P. Schipper, J.L.J. Jan-
sen, F.J.H.M. v Liebergen, and M.I. Koolen, Department of Nephrol-
ogy, Bosch Medicentrum, Den Bosch, University Hospital Nijmegen,
N,jmegen, The Netherlands. Background: In a previous study we
reported on a family with 43 members, two generations, in which 7
persons had hypomagnesemia, hypokalemia and severe chondrocalci-
nosis (CPPD). Since the hypomagnesemia seems to play an important
role in the pathogenesis of the CPPD, this needs further study. Aim: To
investigate, after a baseline period, renal tubular function, that is, distal
tubular chloride reabsorption, urine diluting capacity and tubular reab-
sorption of magnesium in this family (5 of the 7 persons affected were
studied). Methods: Five days before admission the patients started with
a diet containing 4500 mg potassium, 500 mg magnesium and 800 mg
calcium. Day 1, distal fractional chloride reabsorption and urine diluting
capacity were determined during water loading (glucose 5%, 13 mI/mm,
during 3 hours). Day 2, 30 mmol MgSO4 were infused in 3 hours in order
to determine tubular reabsorption maximum (TmMg). Plasma sodium,
potassium, chloride, bicarbonate, calcium, magnesium, plasma renin
activity (PRA) and osmolality were determined and urinary sodium,
potassium, chloride, magnesium, calcium excretion and osmolality
were determined at the end of the control period and every 30 minutes
during the tests. Results: All patients showed a hypokalemia mean 2.9
mmol/liter (normal 3.8—5.0), hypomagnesemia mean 0.52 mmol/liter
(normal 0.8—1.20) and metabolic alkalosis mean HCO3 31 mmol/liter
(normal 20—28). PRA was elevated, mean 8.2 g/1iter:hr (normal 1—6).
Hypocalciuria was seen in all, mean 1.9 mmol/24 hr (normal 2.5—7.5).
All patients showed a decreased distal fractional chloride reabsorption,
mean 0.65 (normal 0.80—0.95) and diminished urine diluting capacity,
mean minimal urine osmolality 97 mOsml/kg (normal 50). TmMg,
ranging from 1.2—1.6 mg/lOO ml GFRII.73 m2, was normal. The renal
magnesium threshold was lowered in all, ranging from 0.6—0.8 mg/l00
ml (normal >1.4). Conclusion: The primary defect in familial hypokal-
emia, hypomagnesemia, might be located in the distal tubule, resulting
in a decreased fractional chloride reabsorption and mild renal Mg loss.
The subsequent hypovolemia might stimulate PRA leading to secondary
renal potassium loss and metabolic alkalosis. The hypocalciuria might
be the result of increased calcium reabsorption due to sodium chloride
loss in the distal tubule.
Do peritoneal permeability and inflammatory mediators change the
days preceding overt peritonitis in CAPD patients? D. Zemel, M.G.H.
Betjes, G.C.M. Koomen, D.G. StruUk, and R.T. Krediet, Renal Unit,
Academic Medical Center, University of Amsterdam and Department
of Cell Biology, Free University of Amsterdam, Amsterdam, The
Netherlands, The effective peritoneal surface area (EPSA) and intrinsic
peritoneal permeability (IPP) are increased during the acute phase of
peritonitis (P). This is accompanied by rises in inflammatory mediators
in dialysate (D) like TNFa, interleukin-6 (11-6) and prostaglandins (PG).
It is unknown whether changes in EPSA, IPP and mediators precede
the onset of overt P. We instructed 5 CAPD patients to store every
nightbag at 4°C. Routinely, each bag was thrown away after 2 days.
Only if patients developed P, all bags were delivered for study. Thus, 2
nightbags immediately prior to the first P bag were available for
analysis. Patients with P were subsequently followed on 8 days during
P and once after recovery (control). D samples were taken daily
(nightbags) for TNFa, 11-6, POE2, 6kFla, F2, TxB2 and serum
proteins. Clearance (Cl) of p2-microglobulin (j32m) was used as indicator
of the EPSA. IPP was characterized by the peritoneal restriction
coefficient (rc). Low rc means high IPP. Two night dwells prior to the
onset of P were available in 4 patients, one in 1 patient. Time points
were 8 and 4 dwells before P(—8, —4) in patient 1, —7, —3 (patient 2),
—21, —1 (patient 3), —2 (patient 4), —8, —4 (patient 5). Cell counts were
always < 100. 106/liter. In contrast, bacterial cultures were already
positive in patients 2, 3 and 4 at t =
—4, —2, —l dwells and after
prolonged culture in patient 1 at t = —7. No changes occurred prior to
P in Clm, rc or PG. However, a rise in TNFa and 11-6 in D was
observed in those effluents obtained no longer than 2 dwells before the
onset of overt P. During consecutive follow-up of P median Cl,32,,,
(l/min) and mediators in D (pg/mm) were increased on day I (first P
bag) and subsequently decreased to control. Clm: 1388 to 900; TNFa:
1290 to 29; 11-6: 12361 to 59; POE2: 1160 to 172; 6kFla: 2360 to 79; F2,,:
259 to 56; TxB2: 281 to 49. Rc increased from 2.05 (day 1) to 2.36
(control). We conclude that increases in EPSA, IPP and inflammatory
mediators observed during P are preceded by changes in TNFa and 11-6
in D. These occur shortly (2 dwells) before the onset of overt P. The
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presence of bacteria at an earlier stage suggests a certain "threshold" in
bacterial load that must be reached before host defense mechanisms are
activated.
In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants: A
double-blind study in renal transplant recipients. Karine J. Parley/jet,
Ineke, f.M. ten Berge, Si-la Yong, Janto Surachno, Joep M. Wilmink,
and Peter Th,A. Schellekens, Renal Transplant Unit, Department of
Internal Medicine Academic Medical Center, University of Amster-
dam, Amsterdam, The Netherlands. Side effects after the first admin-
istration of OKT3, a murine anti-CD3 monoclonal antibody (Mab) of the
IgG2a class, are attributed to the release of cytokines as a result of
transient activation of T cells and monocytes. T cell stimulation by
OKT3 is supposed to be dependent of interaction with Fc receptors
(FcR) on human monocytes. As human monocytes do not possess an
FcR for murine IgA, it is to be expected that an anti-CD3 Mab of the
IgA class causes less side effects than its IgG2a switch variant. To test
this hypothesis we treated 20 renal transplant patients in a double-blind
fashion with either IgG2a of IgA anti-CD3 induction therapy: 0.5 mg
anti-CD3 twice daily during 10 days. Side effects were significantly less
after IgA than after IgG2a. Both IgA and IgG2a resulted in a complete
depletion of CD3+ cells, but after IgA, CD3 depletion was of shorter
duration than after IgG2a. IL-6 and gamma IFN increased significantly
after IgG2a, but not after IgA. The TNF peak level occurring after IgA
was significantly lower than, although not completely absent, after
IgG2a. In plasma the complement activation products C3a-desarg and
C4b/c were not detectable. Plasma levels of neutrophil activation
products lactoferrin and elastase-a1-antitrypsin complexes increased
only after IgG2a. The same holds true for parameters of fibrinolysis tPA
and PAPc. Parameters of coagulation are currently being tested. Our
results indicate that an anti-CD3 Mab of the IgA class causes little or no
cytokine release and less side effects than its IgG2a switch variant.
2,8-dihydroxyadenine stone formation after renal transplantation. F.
Huysmans, D. de Jong, H. DUkman, F. van Liebergen, L. Monnens, R.
D'Abreu, and K. Assmann, Departments of Nephrology, Pediatrics,
and Pathology, University Hospital Nijmegen, and Bosch Medicen-
trum, Den Bosch, The Netherlands. A 56 year old man with a medical
history of urolithiasis of unknown origin underwent a renal transplan-
tation in November 1991. From the start of allopurinol treatment in 1977
stone formation had stopped. At transplantation all previous medica-
tion, including allopurinol, was discontinued. After an initial maximum
level of endogenous creatinine clearance of 32 mI/mm several episodes
of histologically proven acute interstitial rejections could not be treated
successfully. Hemodialysis was started from day 80 after transplanta-
tion. The transplanted kidney had to be removed nine months later
because of severe chronic vascular rejection. Renal biopsies were taken
on days 10, 31, and 51 after transplantation. In all these biopsies, as well
as in the removed renal graft, birefringent crystals were present in the
tubuli and in the interstitium, either free in the tubular lumina or located
in tubular or interstitial cells. The crystals were brownish colored and
resembled oxalate crystals. The urinary sediments obtained before and
after removal of the graft also contained these crystals. Biopsies taken
from the contralateral kidney of the same donor did not demonstrate
these crystals, X-ray diffraction microanalysis of the crystalline mate-
rial obtained from the kidney biopsies and the urine showed that the
crystals were composed of 2,8-dihydroxyadenine (2,8-DHA). The lev-
els of 2,8-DHA in urine and plasma samples as measured with HPLC
were elevated. The urinary excretion of calcium, urate and oxalate was
normal. The adenine phosphoribosyltransferase activity (APRT) mea-
sured four times in the patient's lymphocytes using an assay with
C'4-adenine as substrate was very low (0.79 0.56 nmol/l06 cells/hr.
compared to 10.70 0.64 in healthy controls and 9.58 1.61 in patients
on hemodialysis). Homozygosity for deficiency of this enzyme results
in the accumulation of adenine and its oxidation product 2,8-DHA,
which may lead to stone formation and severe renal failure. It is not
clear whether APRT deficiency contributed to renal damage in the
patient described here. In conclusion, 2,8-DHA urolithiasis due to
APRT deficiency, a probably underdiagnosed condition, should also be
considered in case of urinary stone or crystal formation after renal
transplantation. This is especially important, since 2,8-DHA crystal
formation can effectively be inhibited with allopurinol.
Effect of immunosuppressive therapy on serum lipid levels after renal
transplantation. L.B, Hi/brands, A.J. Hoitsma, P.N.M. Demacker,
R.A.P. Koene, University Hospital Nijmegen, Njmegen, The Nether-
lands. Disturbances of lipid metabolism are frequently encountered
after renal transplantation (Tx) and have been ascribed to the use of
cyclosporine (CsA) and steroids. We investigated the effect of different
immunosuppressive treatment regimens on serum lipid levels in a
prospective randomized trial. All patients received CsA and prednisone
during the first 3 months after Tx. Subsequently, they were randomized
to either withdrawal of prednisone (resulting in CsA monotherapy; C, N
= 42) or to conversion of CsA to azathioprine (A + P, N = 41). Serum
levels of total cholesterol (TC), LDL-cholesterol (LDL), HDL-choles-
terol (HDL), and triglycerides (TG) were measured at 2, 3, 5, 6, 9, and
12 months after Tx. The means of the values obtained at 2 and 3 months
were used for calculation of changes after randomization. Both groups
did not differ with respect to sex or age. At baseline there were no
significant differences in serum lipid levels (C vs. A + P in mmol/liter:
TC: 6.09 1.73 vs. 6.05 1.32, LDL: 3.95 1.54 vs. 3.85 1.03,
HDL: 1.39 0.41 vs. 1.35 0.41, TG: 1.86 1.01 vs. 2.04 1.02).
After randomization, TC levels did not change while a small but
significant increase of LDL was observed in both groups. Levels of
HDL decreased significantly in either group, but the fall was signifi-
cantly larger in C than in A + P (: —22.9 28.2% vs. —11.9 25.7%
at 12 m). TG rose markedly in C ( = +47.2 83.9% at 12 m) while it
did not change in A + P, resulting in a significant difference between
both groups. Since the combination of high TG and low HDL increases
the risk of cardiovascular diseases, these observations have strong
clinical relevance. Conclusion: CsA monotherapy beyond three months
after renal transplantation leads to a more atherogenic serum lipid
profile (lower HDL and higher TG) when compared with conversion
from CsA to azathioprine.
